- Home
- DLTH vs TLSA Comparison
DLTH vs TLSA Comparison
Compare DLTH & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DLTH | TLSA |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.0M | 164.1M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DLTH | TLSA |
|---|---|---|
| Price | $3.52 | $1.36 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 63.3K | ★ 237.1K |
| Earning Date | 06-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.12 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $565,184,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.80 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.82 | $1.14 |
| 52 Week High | $4.66 | $2.60 |
Technical Indicators
Market Signals| Indicator | DLTH | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 55.67 | 43.62 |
| Support Level | $3.39 | $1.24 |
| Resistance Level | $3.63 | $1.54 |
| Average True Range (ATR) | 0.22 | 0.15 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 75.15 | 5.47 |
Price Performance
Historical ComparisonAbout DLTH Duluth Holdings Inc. Class B
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.